Skip to main content

Table 1 Patient’s demographics and tumor characteristics and association of ALKBH5 levels with clinicopathological features

From: m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC

Characteristics No. of patients, N = 60 (%) P value
Patients Parameter
 Age (years)   0.871
 Average [range] 53 [30–81]  
   < 53 20 (33.3)  
   ≥ 53 40 (66.7)  
 Gender   0.714
  Male 32 (53.3)  
  Female 28 (46.7)  
Smoking history
 Smoker 35 (58.3) 0.12
 Non-smoker 25 (41.7)  
Tumor Characteristics
 Tumor size (cm)   0.009**
   < 4 10 (16.7)  
   ≥ 4 50 (83.3)  
 Differentiation   0.044*
  Poor 41 (68.3)  
  Well-moderate 19 (31.7)  
 Lymph node metastasis 0.014*
  N- 9 (15.0)  
  N+ 51 (85.0)  
 Distant metastasis   0.008**
  M- 8 (13.3)  
  M+ 52 (86.7)  
Expression of ALKBH5
 Protein level
  high 2 (3.3) 0.086
  median 8 (13.3) 0.078
  low 50 (83.4) 0.002**
 mRNA level
  high 3 (5.0) 0.074
  median 9 (15.0) 0.063
  low 48 (80.0) 0.001**
Expression of YAP
 Protein level
  high 46 (76.6) 0.008**
  median 9 (15.5) 0.062
  low 5 (7.9) 0.865
 mRNA level
  high 48 (80.0) 0.005**
  median 8 (13.3) 0.084
  low 4 (6.7) 0.754
  1. Differences between experimental groups were assessed by Student’s t-test or one-way analysis of variance. Data represent mean ± SD. *p < 0.05; **p < 0.01